JSH-23

JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC₅₀ of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation^[1]. IC50 & Target:IC50: 7.1 μM (NF-κB) In Vitro:JSH-2 (1-300 μM; 24 hours) at <100 μM does not show significant cytotoxic effects on the RAW 264.7 cells^[1].
Nuclear amount of NF-κB p65 is markedly increased upon exposure to LPS for 1 h. Treatment of JSH-23 (30 μM; 1 hours) to LPS- stimulated RAW 264.7 cells decreases nuclear content of NF-κB p65 in a dose-dependent manner^[1]. In Vivo:JSH-23 (1 mg/kg, 3 mg/kg; orally administered; daily; for 2 weeks) significantly reverses the nerve conduction and nerve blood flow deficits seen in diabetic rats^[2].